An investigational drug from Veru helped preserve lean mass in patients taking Wegovy, though some experts raised questions ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

It does not apply to 1.7 mg or 2.4 mg semaglutide (Wegovy), which is indicated for chronic weight management. Chronic kidney disease is a common complication of type 2 diabetes; around 40% of ...